CT-868
A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
Carmot Therapeutics, Inc · Phase 2 · Completed · Enrollment 103
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo | n/r | n/r | n/r | n/r |
| CT-868 1.75 mg | n/r | n/r | n/r | n/r |
| CT-868 4.0 mg | n/r | n/r | n/r | n/r |
Not shown
- Placebo: endpoint not reported
- CT-868 1.75 mg: endpoint not reported
- CT-868 4.0 mg: endpoint not reported